Tenderwize
Retour à la recherche

Safinamid_TK, HEK, hkk

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 29, 2027 · 246 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-06 - Safinamid

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No guaranteed volume or minimum purchase; the actual revenue depends on the number of prescriptions and competition.

Submission deadlines for timely pharmacy software inclusion are strict (3rd of previous month). Late submissions may de...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for Safinamid pharmaceutical products under §130a Abs. 8 SGB V.
  • Contract covers all exchangeable finished medicinal products of the contractor.
Afficher le résumé complet

Open-house discount agreement procedure for pharmaceutical product Safinamid, conducted by Techniker Krankenkasse (TK) on behalf of HEK and hkk. The goal is to conclude non-exclusive rebate contracts with all eligible pharmaceutical entrepreneurs. Contract duration max 12 months from 01.05.2026 to 30.04.2027. Participation possible at any time during the contract period. No individual negotiations; uniform conditions.

Risques

No guaranteed volume or minimum purchase; the actual revenue depends on the number of prescriptions and competition.

Submission deadlines for timely pharmacy software inclusion are strict (3rd of previous month). Late submissions may de...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of §4 Abs. 18 AMG for the offered medicinal products.
  • Company seat must be in Germany, another EU member state, or EEA state (§9 Abs.2 AMG).
  • Local representatives can only participate if they themselves are pharmaceutical entrepreneurs for the offered products.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Safinamid_TK, HEK, hkk

Discount agreement for Safinamid active ingredient. Scope covers all exchangeable finished medicinal products of the contractor as per framework agreement. Participation of HEK and/or hkk depends on lot designation.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Apr 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Apr 29, 2027

Détails de la procédure

Date de publication
26 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
214489-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3